Bernard Mach, MD, PhD

Founder of Novimmune, of which he is Chairman …. Former professor and director of the Department of Genetics and Microbiology, Faculty of Medicine, University of Geneva, Bernard Mach is the inventor of cDNA cloning and is specialized in the molecular biology of immune response genes. B. Mach was co-founder and member of the SAB of Biogen (1978-1992). He was Chairman of the Lombard Odier Immunology Fund Scientific Advisory Board since 1994. Member of Aravis Venture Partners. Member of the Board of Directors of Serono and former board member of Lonza as well as Scientific Advisor to various institutes and companies. He was a Member of the Swiss Science Council (1974-1984), is a special member of the Swiss Academy of Medical Sciences and is a Member of the French Academy of Sciences.

Richard Ulevitch, PhD, San Diego

Richard Ulevitch is chairman of the Department of Immunology at Scripps Research Institute in La Jolla California. He is, among other affiliations, on the advisory panels of the National Institute of Health, the American Heart Association, The Food and Drug Administration (FDA) and the American Association of Immunologists. Dr. Ulevitch is specialized in signal transduction pathways within cells. He is an expert in the field of endotoxin activation and septic shock. He is an advisor to different institutes and several biotechnology companies.

Hartmut Wekerle, MD, Munich

Professor and Director at the Max Planck Institute of Neurobiology in Munich. Professor Wekerle served as Chairman (Dean) of the Biological-Medical Section of the Max Planck Institute (1999-2003). In 2002, Chairman of the SAB of the Center of Immunology of the Weizmann Institute. Initiated during his postdoctoral training at the Weizmann Institute, Professor Wekerle’s interest was focused on the cellular basis of immunological self-tolerance and autoimmunity. Specifically he has been studying the pathogenesis of autoimmune nervous system diseases, especially Multiple Sclerosis, over the past 20 years. He serves on advisory boards of several national MS societies and is member of the editorial boards of numerous international journals.

Rolf Zinkernagel, MD, PhD, Zurich

Professor and head of the Institute of Experimental Immunology, Department of Pathology at the University of Zurich. Among other professional memberships, he is a member of the Swiss Society of Allergy and Immunology, the Swiss Society of Pathology, the Swiss Society of Microbiology, the Swiss society of Cell and Molecular Biology and the US Academy of Sciences. He is a member of the board of directors of Novartis International AG and Cytos AG, and an advisor to different institutes and biotechnology companies. Dr. Zinkernagel is specialized in infectious diseases and immunopathology. He is a pioneer in research on self-nonself discrimination in immunology. He received the Nobel Prize in medicine (1996).